275 related articles for article (PubMed ID: 19139110)
21. FTY720 induces apoptosis in multiple myeloma cells and overcomes drug resistance.
Yasui H; Hideshima T; Raje N; Roccaro AM; Shiraishi N; Kumar S; Hamasaki M; Ishitsuka K; Tai YT; Podar K; Catley L; Mitsiades CS; Richardson PG; Albert R; Brinkmann V; Chauhan D; Anderson KC
Cancer Res; 2005 Aug; 65(16):7478-84. PubMed ID: 16103102
[TBL] [Abstract][Full Text] [Related]
22. Brevilin A, a novel natural product, inhibits janus kinase activity and blocks STAT3 signaling in cancer cells.
Chen X; Du Y; Nan J; Zhang X; Qin X; Wang Y; Hou J; Wang Q; Yang J
PLoS One; 2013; 8(5):e63697. PubMed ID: 23704931
[TBL] [Abstract][Full Text] [Related]
23. CHIR-258, a novel, multitargeted tyrosine kinase inhibitor for the potential treatment of t(4;14) multiple myeloma.
Trudel S; Li ZH; Wei E; Wiesmann M; Chang H; Chen C; Reece D; Heise C; Stewart AK
Blood; 2005 Apr; 105(7):2941-8. PubMed ID: 15598814
[TBL] [Abstract][Full Text] [Related]
24. Dihydroorotate dehydrogenase inhibitor A771726 (leflunomide) induces apoptosis and diminishes proliferation of multiple myeloma cells.
Baumann P; Mandl-Weber S; Völkl A; Adam C; Bumeder I; Oduncu F; Schmidmaier R
Mol Cancer Ther; 2009 Feb; 8(2):366-75. PubMed ID: 19174558
[TBL] [Abstract][Full Text] [Related]
25. JAK kinase inhibition abrogates STAT3 activation and head and neck squamous cell carcinoma tumor growth.
Sen M; Pollock NI; Black J; DeGrave KA; Wheeler S; Freilino ML; Joyce S; Lui VW; Zeng Y; Chiosea SI; Grandis JR
Neoplasia; 2015 Mar; 17(3):256-64. PubMed ID: 25810010
[TBL] [Abstract][Full Text] [Related]
26. Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
Raje N; Hideshima T; Mukherjee S; Raab M; Vallet S; Chhetri S; Cirstea D; Pozzi S; Mitsiades C; Rooney M; Kiziltepe T; Podar K; Okawa Y; Ikeda H; Carrasco R; Richardson PG; Chauhan D; Munshi NC; Sharma S; Parikh H; Chabner B; Scadden D; Anderson KC
Leukemia; 2009 May; 23(5):961-70. PubMed ID: 19151776
[TBL] [Abstract][Full Text] [Related]
27. Dihydrocelastrol inhibits multiple myeloma cell proliferation and promotes apoptosis through ERK1/2 and IL-6/STAT3 pathways in vitro and in vivo.
Hu L; Wu H; Li B; Song D; Yang G; Chen G; Xie B; Xu Z; Zhang Y; Yu D; Hou J; Xiao W; Sun X; Chang G; Zhang Y; Gao L; Dai B; Tao Y; Shi J; Zhu W
Acta Biochim Biophys Sin (Shanghai); 2017 May; 49(5):420-427. PubMed ID: 28338993
[TBL] [Abstract][Full Text] [Related]
28. Synergistic anti-tumor effect of combined inhibition of EGFR and JAK/STAT3 pathways in human ovarian cancer.
Wen W; Wu J; Liu L; Tian Y; Buettner R; Hsieh MY; Horne D; Dellinger TH; Han ES; Jove R; Yim JH
Mol Cancer; 2015 May; 14():100. PubMed ID: 25928246
[TBL] [Abstract][Full Text] [Related]
29. Inhibitory effect of baicalein on IL-6-mediated signaling cascades in human myeloma cells.
Liu S; Ma Z; Cai H; Li Q; Rong W; Kawano M
Eur J Haematol; 2010 Feb; 84(2):137-44. PubMed ID: 19878271
[TBL] [Abstract][Full Text] [Related]
30. The Novel Pan-PIM Kinase Inhibitor, PIM447, Displays Dual Antimyeloma and Bone-Protective Effects, and Potently Synergizes with Current Standards of Care.
Paíno T; Garcia-Gomez A; González-Méndez L; San-Segundo L; Hernández-García S; López-Iglesias AA; Algarín EM; Martín-Sánchez M; Corbacho D; Ortiz-de-Solorzano C; Corchete LA; Gutiérrez NC; Maetos MV; Garayoa M; Ocio EM
Clin Cancer Res; 2017 Jan; 23(1):225-238. PubMed ID: 27440267
[TBL] [Abstract][Full Text] [Related]
31. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism.
Dai Y; Landowski TH; Rosen ST; Dent P; Grant S
Blood; 2002 Nov; 100(9):3333-43. PubMed ID: 12384435
[TBL] [Abstract][Full Text] [Related]
32. Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
Bhutani M; Pathak AK; Nair AS; Kunnumakkara AB; Guha S; Sethi G; Aggarwal BB
Clin Cancer Res; 2007 May; 13(10):3024-32. PubMed ID: 17505005
[TBL] [Abstract][Full Text] [Related]
33. Potential crosstalk of the interleukin-6-heme oxygenase-1-dependent mechanism involved in resistance to lenalidomide in multiple myeloma cells.
Wu W; Ma D; Wang P; Cao L; Lu T; Fang Q; Zhao J; Wang J
FEBS J; 2016 Mar; 283(5):834-49. PubMed ID: 26700310
[TBL] [Abstract][Full Text] [Related]
34. Enzastaurin (LY317615), a protein kinase Cbeta inhibitor, inhibits the AKT pathway and induces apoptosis in multiple myeloma cell lines.
Rizvi MA; Ghias K; Davies KM; Ma C; Weinberg F; Munshi HG; Krett NL; Rosen ST
Mol Cancer Ther; 2006 Jul; 5(7):1783-9. PubMed ID: 16891464
[TBL] [Abstract][Full Text] [Related]
35. JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.
De Vos J; Jourdan M; Tarte K; Jasmin C; Klein B
Br J Haematol; 2000 Jun; 109(4):823-8. PubMed ID: 10929036
[TBL] [Abstract][Full Text] [Related]
36. The phosphatase of regenerating liver-3 (PRL-3) is important for IL-6-mediated survival of myeloma cells.
Slørdahl TS; Abdollahi P; Vandsemb EN; Rampa C; Misund K; Baranowska KA; Westhrin M; Waage A; Rø TB; Børset M
Oncotarget; 2016 May; 7(19):27295-306. PubMed ID: 27036022
[TBL] [Abstract][Full Text] [Related]
37. The histone deacetylase inhibitor ITF2357 has anti-leukemic activity in vitro and in vivo and inhibits IL-6 and VEGF production by stromal cells.
Golay J; Cuppini L; Leoni F; Micò C; Barbui V; Domenghini M; Lombardi L; Neri A; Barbui AM; Salvi A; Pozzi P; Porro G; Pagani P; Fossati G; Mascagni P; Introna M; Rambaldi A
Leukemia; 2007 Sep; 21(9):1892-900. PubMed ID: 17637810
[TBL] [Abstract][Full Text] [Related]
38. A novel requirement for Janus kinases as mediators of drug resistance induced by fibroblast growth factor-2 in human cancer cells.
Carmo CR; Lyons-Lewis J; Seckl MJ; Costa-Pereira AP
PLoS One; 2011; 6(5):e19861. PubMed ID: 21625473
[TBL] [Abstract][Full Text] [Related]
39. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma.
Fulciniti M; Hideshima T; Vermot-Desroches C; Pozzi S; Nanjappa P; Shen Z; Patel N; Smith ES; Wang W; Prabhala R; Tai YT; Tassone P; Anderson KC; Munshi NC
Clin Cancer Res; 2009 Dec; 15(23):7144-52. PubMed ID: 19934301
[TBL] [Abstract][Full Text] [Related]
40. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]